BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 9.1% in January

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 15,720,000 shares, a drop of 9.1% from the December 31st total of 17,290,000 shares. Based on an average daily trading volume, of 2,050,000 shares, the short-interest ratio is currently 7.7 days.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of BCRX. Venturi Wealth Management LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $48,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. KBC Group NV lifted its stake in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the period. Finally, Quantinno Capital Management LP bought a new position in BioCryst Pharmaceuticals during the third quarter worth about $82,000. 85.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several recent analyst reports. Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday. Finally, Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Stock Up 0.4 %

BioCryst Pharmaceuticals stock opened at $7.90 on Monday. The business’s 50-day simple moving average is $7.63 and its 200 day simple moving average is $7.69. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -12.95 and a beta of 1.76. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period last year, the business posted ($0.19) EPS. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.